NEW YORK, NY / ACCESSWIRE / June 5, 2023 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Horizon Bancorp, Inc. (NASDAQ:HBNC)
CONTACT JAKUBOWITZ ABOUT HBNC:
https://claimyourloss.com/securities/horizon-class-action-loss-submission-form/?id=40372&from=1
Class Period: March 9, 2022 - March 10, 2023
Lead Plaintiff Deadline: June 20, 2023
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company maintained deficient internal accounting controls relating to its classification of certain loan balances and securities; (ii) as a result of the foregoing deficiencies, throughout 2022 the Company issued quarterly financial statements containing errors that would require subsequent revision; (iii) restatement of the foregoing financial statements would hinder the Company's ability to timely file its annual report for 2022; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
LivePerson, Inc. (NASDAQ:LPSN)
CONTACT JAKUBOWITZ ABOUT LPSN:
https://claimyourloss.com/securities/liveperson-class-action-loss-submission-form/?id=40372&from=1
Class Period : May 10, 2022 - March 16, 2023
Lead Plaintiff Deadline: June 23, 2023
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) LivePerson failed to address any material weaknesses with internal controls; (2) LivePerson's third quarter financial statements, ended in September 30, 2022 failed to disclose its subsidiary, WildHealth's, suspension of Medicare reimbursement; (3) as a result, LivePerson's fourth quarter 2022 revenue would be affected; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
CONTACT JAKUBOWITZ ABOUT FULC:
https://claimyourloss.com/securities/fulcrum-class-action-loss-submission-form/?id=40372&from=1
Class Period: March 3, 2022 - March 8, 2023
Lead Plaintiff Deadline: June 27, 2023
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/759269/LAWSUITS-FILED-AGAINST-HBNC-LPSN-and-FULC--Jakubowitz-Law-Pursues-Shareholders-Claims
